carvedilol has been researched along with losartan potassium in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Clark, AL; Cleland, JG; Coletta, AP; Nikitin, NP | 1 |
Besler, C; Doerries, C; Giannotti, G; Landmesser, U; Lüscher, TF | 1 |
Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL | 1 |
2 review(s) available for carvedilol and losartan potassium
Article | Year |
---|---|
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Antigens, CD34; Atherosclerosis; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; Cell Differentiation; Coronary Disease; Endothelium, Vascular; Erythropoietin; Ethanolamines; Glycoproteins; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Nebivolol; Neovascularization, Physiologic; Oxidative Stress; Peptides; PPAR gamma; Propanolamines; Receptors, Angiotensin; Regeneration; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Carbazoles; Cardiolipins; Cardiotonic Agents; Carvedilol; Doxorubicin; Erythropoietin; Heart; Heart Diseases; Humans; Lipid Peroxidation; Liposomes; Neoplasms; Piperazines; Propanolamines; Purines; Razoxane; Risk Factors; Sildenafil Citrate; Sulfones; Survivors; Ventricular Dysfunction, Left | 2012 |
2 other study(ies) available for carvedilol and losartan potassium
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.
Topics: Carbazoles; Carvedilol; Child; Cholesterol, LDL; Clinical Trials as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Fluorobenzenes; Heart Failure; Humans; Myocardial Infarction; Propanolamines; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrafiltration | 2006 |